Liposomal Irinotecan and Apatinib in ES-SCLC

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study ID
NCT06749691
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Small Cell Lung Cancer Extensive Stage

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.

Key Dates

Start date
Dec 28, 2024
Status verified
Dec 2024
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Liposomal Irinotecan and Apatinib

Primary Outcome Measure

Progression-Free-Survival rate at 6 months [ Time Frame: From enrollment at 6 months ]

Central Contacts

Related Studies